| Date | Title | Description | |
|---|---|---|---|
| 26 Jul 2023 | On P&L | The Company releases the first half 2023 financial results presentation | Download |
| 26 Jul 2023 | On buy-back programmes | The Company reports the commencement, effective as of today, 26 July 2023, of a share buyback program. | Download |
| 10 May 2023 | On P&L | The Company releases the first quarter 2023 financial results presentation | Download |
| 10 May 2023 | On P&L | The Company releases the press release related to the first quarter 2023 financial results | Download |
| 25 Apr 2023 | On business and financial situation | ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 03 Nov 2021 | On business and financial situation | The Company releases the press release related to the first nine months 2021 financial results | Download |
| 21 Oct 2021 | Liquidity and counterparty agreements | Download | |
| 21 Oct 2021 | On business and financial situation | The Company informs of the delay in the decision on Risperidone ISM® by the U.S. Food and Drug Administration (“FDA”). | Download |
| 07 Oct 2021 | Liquidity and counterparty agreements | Download | |
| 04 Oct 2021 | Liquidity and counterparty agreements | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 03 Jul 2012 | Información sobre dividendos | Download | |
| 13 Jun 2012 | Convocatorias y Acuerdos de Juntas y Asambleas Generales | Download | |
| 26 Apr 2012 | Información sobre resultados (2) | Download | |
| 26 Apr 2012 | Información sobre resultados | Download | |
| 26 Apr 2012 | Convocatorias y Acuerdos de Juntas y Asambleas Generales | Download |